Patents Assigned to Genexine Inc.
-
Publication number: 20190224281Abstract: A method for treating growth hormone deficiency, including administering a human growth hormone fusion protein (GX-H9). A method includes administering a pharmaceutical composition containing an hGH fusion protein (GX-H9) and a pharmaceutically acceptable carrier, wherein the fusion protein (GX-H9) is administered once a week at a dose of 0.4 to 1.6 mg per body weight kg of a pediatric patient, or administered once every two weeks at a dose of 0.8 to 3.2 mg per body weight kg of a pediatric patient.Type: ApplicationFiled: August 30, 2017Publication date: July 25, 2019Applicants: GENEXINE, INC., HANDOK INC.Inventors: Tae Kyung KIM, Jung Won WOO, Joan Yoon Ji LEE, Young-Joo AHN, Ji-Eun CHA, Hyou Young RHIM, Woo Ick JANG
-
Publication number: 20190106471Abstract: The present invention provides a modified interleukin-7 and a use thereof. The modified IL-7 or an IL-7 fusion protein of the present invention comprising the same can be obtained in high yield, and biologically active in viral infection and cancer models. Therefore, they can be used for the prevention and treatment of various diseases.Type: ApplicationFiled: December 13, 2018Publication date: April 11, 2019Applicant: GENEXINE, INCInventors: Se Hwan YANG, Donghoon CHOI, Hye Seong LIM
-
Publication number: 20190062396Abstract: The present invention relates to a composition for the diagnosis and treatment of recurrent thyroid cancer comprising recombinant human thyroid stimulating hormone (rhTSH) and a method for producing the recombinant human thyroid hormone. The method for producing recombinant human thyroid hormone according to the present invention can effectively produce rhTSH despite being cultured through fed-batch culture, and has a high purification yield and purity. Therefore, the recombinant thyroid stimulating hormone produced by the method can be usefully used for the diagnosis or treatment of recurrent thyroid cancer.Type: ApplicationFiled: November 4, 2016Publication date: February 28, 2019Applicants: GENEXINE, INC., PROGEN CO., LTD.Inventors: Young Chul SUNG, Zungyoon YANG
-
Patent number: 10208099Abstract: The present invention provides a modified interleukin-7 and a use thereof. The modified IL-7 or an IL-7 fusion protein of the present invention comprising the same can be obtained in high yield, and biologically active in viral infection and cancer models. Therefore, they can be used for the prevention and treatment of various diseases.Type: GrantFiled: June 10, 2016Date of Patent: February 19, 2019Assignee: GENEXINE, INC.Inventors: Se Hwan Yang, Donghoon Choi, Hye Seong Lim
-
Publication number: 20180353573Abstract: The present invention relates to a pharmaceutical composition comprising an interleukin-7 fusion protein to which an immunoglobulin Fc region has been fused for preventing or treating diseases caused by influenza virus A. The fusion protein comprising the immunoglobulin Fc region and IL-7 according to the present invention protects the body from infection due to influenza virus A and thus can treat diseases which can be caused by the virus.Type: ApplicationFiled: November 30, 2016Publication date: December 13, 2018Applicant: GENEXINE, INC.Inventors: Moon Cheol KANG, Young Woo CHOI, Donghoon CHOI, Young Chul SUNG
-
Publication number: 20180327472Abstract: Provided is a pharmaceutical formulation comprising a modified IL-7 protein. More particularly, it comprises (a) a modified IL-7 fusion protein; (b) a basal buffer with a concentration of 10 to 50 mM; (c) a sugar with a concentration of 2.5 to 5 w/v %; and (d) a surfactant with a concentration of 0.05 to 6 w/v %. Such pharmaceutical formulation of a modified IL-7 fusion protein does not show aggregates formation, but shows protective effects on proteins under stress conditions such as oxidation or agitation, and thus can effectively be used for the treatment of a patient.Type: ApplicationFiled: November 2, 2016Publication date: November 15, 2018Applicant: GENEXINE, INC.Inventors: Donghoon CHOI, Changyong EUN, Seong Hoon JEONG, Jun Yeul LIM
-
Publication number: 20180319858Abstract: The present invention relates to a pharmaceutical composition comprising an immunoglobulin Fc region and an IL-7 fusion protein. Specifically, when a fusion protein comprising the immunoglobulin Fc region and IL-7 is administered to an affected area, a strong immune response is induced in the body and thus allows human papillomavirus-caused diseases to be prevented or treated.Type: ApplicationFiled: December 2, 2016Publication date: November 8, 2018Applicant: GENEXINE, INC.Inventors: Moon Cheol KANG, Young Woo CHOI, Donghoon CHOI, Young Chul SUNG
-
Publication number: 20180273596Abstract: The present invention provides a modified interleukin-7 and a use thereof. The modified IL-7 or an IL-7 fusion protein of the present invention comprising the same can be obtained in high yield, and biologically active in viral infection and cancer models. Therefore, they can be used for the prevention and treatment of various diseases.Type: ApplicationFiled: June 5, 2018Publication date: September 27, 2018Applicant: GENEXINE, INC.Inventors: Se Hwan YANG, Donghoon CHOI, Hye Seong LIM
-
Publication number: 20180264082Abstract: The present invention relates to a method for treating anemia using a long-acting EPO formulation, and more specifically, a method for treating patients with anemia by confirmation of safe, long-acting, and optimal effective dosage and usage in administering a fusion polypeptide which comprises an EPO and an immunoglobulin hybrid Fc to patients with anemia. The method of administering the fusion polypeptide employs an appropriate dosage and usage which not only shows an excellent long-acting property compared to the existing EPO products but also minimizes cardiovascular side effects that may occur due to a rapid increase in hemoglobin level, which is an effect of anemia treatment.Type: ApplicationFiled: January 8, 2016Publication date: September 20, 2018Applicants: GENEXINE, INC., GREEN CROSS CORPORATIONInventors: Sang-In YANG, Jung-Won WOO, Se Hwan YANG, Young Chul SUNG, Doo Hong PARK, Min Woo KIM
-
Publication number: 20170362293Abstract: The present invention relates to a fusion polypeptide containing a glucagon-like peptide (GLP) and an immunoglobulin hybrid Fc, and more specifically, to a fusion polypeptide with an increased half-life and improved efficacy compared to the conventional fusion polypeptide based on the discovery of an immunoglobulin hybrid Fc suitable for GLP or analogs thereof, and a pharmaceutical composition for treating diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, containing the fusion polypeptide. The fusion polypeptide of the present invention has an increased half-life and improved resistance to DPP-4 enzyme compared to those of GLP-1 and GLP-2, and it thus has improved drug efficacy in treating diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, compared to those of the conventional drugs.Type: ApplicationFiled: December 31, 2015Publication date: December 21, 2017Applicant: GENEXINE, INC.Inventors: Young Chul SUNG, Se Hwan YANG, Mi Sun BYUN, Sang In YANG, Eun Ju SHIN
-
Publication number: 20170304385Abstract: This invention relates to the treatment of cervical tumor caused by human papillomavirus (HPV) infection. In particular, the invention provides methods for improving cervical tumor treatment and methods for treating cervical tumor caused by HPV infection using a polynucleotide encoding an E6/E7 fusion protein.Type: ApplicationFiled: August 14, 2015Publication date: October 26, 2017Applicant: GENEXINE, Inc.Inventors: Hyun-Tak JIN, HYE SEONG LIM, YOU SUK SUH, EUN JOO NAM
-
Publication number: 20170189476Abstract: The present invention relates to a fusion protein composed of the extracellular domain of PD-L1 and a modified immunoglobulin Fc region. The extracellular domain of PD-L1 and a fragment thereof have excellent immunomodulatory activity, and can be used as an immunomodulatory agent if a modified immunoglobulin Fc region is coupled thereto. Accordingly, the PD-L1 fusion protein according to the present invention demonstrated its excellent effect in disease models of inflammatory bowel disease, colitis, psoriasis, asthma and arthritis, and thus can be very effectively used for the treatment of such diseases.Type: ApplicationFiled: May 26, 2015Publication date: July 6, 2017Applicants: GENEXINE, INC., POSTECH ACADEMY-INDUSTRY FOUNDATIONInventors: Young Chul SUNG, Ji Yeung LEE, Mi-Young SONG, Hye Seong LIM, Byung Ha LEE
-
Publication number: 20170158746Abstract: The present invention provides a modified interleukin-7 and a use thereof. The modified IL-7 or an IL-7 fusion protein of the present invention comprising the same can be obtained in high yield, and biologically active in viral infection and cancer models. Therefore, they can be used for the prevention and treatment of various diseases.Type: ApplicationFiled: June 10, 2016Publication date: June 8, 2017Applicant: Genexine, Inc.Inventors: Se Hwan YANG, Donghoon CHOI, Hye Seong LIM
-
Patent number: 9399665Abstract: A composition for preventing or treating cervical cancer comprising a human papillomavirus plasmodium and an immunity enhancer is provided. A fusion protein including a fusion polypeptide recombined to transform a 3D structure of E6 and E7, which are antigens against types 16 and 18 human papillomavirus (HPV), a signal peptide for secreting the fusion polypeptide outside the cells and an immunity enhancer peptide present in an individual is also provided. The fusion protein may be useful in treating HPV-triggered tumors by inducing an immune response specific to the antigens against the HPV types 16 and 18.Type: GrantFiled: March 3, 2015Date of Patent: July 26, 2016Assignee: GENEXINE, Inc.Inventors: Young Chul Sung, Sang Hwan Seo, You Suk Suh
-
Publication number: 20160108105Abstract: Disclosed is a human IgG4 Fc polypeptide variant, including a modified CH2 domain of human IgG4 Fc, wherein the modification contains a replacement of a 6-20 consecutive amino acid sequence from the N-terminus of the CH2 domain of IgG4 with a 4-18 consecutive amino acid sequence from the N-terminus of human IgA1 CH2, a 4-18 consecutive amino acid sequence from the N-terminus of human IgA2 CH2, a 4-18 consecutive amino acid sequence from the N-terminus of human IgD CH2, a 4-18 consecutive amino acid sequence from the N-terminus of human IgE CH2, or a 4-18 consecutive amino acid sequence from the N-terminus of human IgM CH2. The Fc variant imparts to a biologically active polypeptide—the modified Fc variant with a prolonged in-vivo half-life and reduced immunogenic reaction.Type: ApplicationFiled: October 6, 2015Publication date: April 21, 2016Applicant: GENEXINE, INC.Inventors: Se Hwan YANG, Eun Ju SHIN, Jaehan PARK, Eun Joo NAM
-
Patent number: 9000139Abstract: A composition for preventing or treating cervical cancer comprising a human papillomavirus plasmodium and an immunity enhancer is provided. A fusion protein including a fusion polypeptide recombined to transform a 3D structure of E6 and E7, which are antigens against types 16 and 18 human papillomavirus (HPV), a signal peptide for secreting the fusion polypeptide outside the cells and an immunity enhancer peptide present in an individual is also provided. The fusion protein may be useful in treating HPV-triggered tumors by inducing an immune response specific to the antigens against the HPV types 16 and 18.Type: GrantFiled: August 13, 2010Date of Patent: April 7, 2015Assignee: Genexine, Inc.Inventors: Young Chul Sung, Sang Hwan Seo, You Suk Suh
-
Patent number: 8883134Abstract: The present disclosure provides a fusion protein comprising IL-1 receptor antagonist fused to a hybrid Fc. Particularly the present disclosure relates to a fusion protein comprising IL-1 receptor antagonist fused to a human immunoglobulin hybrid Fc fragment. In one embodiment, the hybrid Fc fragment comprises IgD and IgG4. Also provided is a pharmaceutical composition comprising the present fusion protein, which are useful for treating autoimmune disease including rheumatoid arthritis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), psoriasis and diabetes and the like. The present fusion protein with excellent efficacy and reduced side effects is qualified for clinical development as therapeutic antibodies to treat autoimmune disease.Type: GrantFiled: October 19, 2011Date of Patent: November 11, 2014Assignees: Handok Pharmaceuticals, Inc., Genexine, Inc.Inventors: Young Gyu Cho, Hye Jeong Shin, Woon Young Lee, Woo Ick Jang
-
Patent number: 8586038Abstract: Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.Type: GrantFiled: November 19, 2010Date of Patent: November 19, 2013Assignees: Genexine, Inc., Postech Academy-Industry Foundation of Phohang University of Science and Technology (Postech)Inventors: Sehwan Yang, Young Chul Sung
-
Patent number: 8586531Abstract: Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.Type: GrantFiled: June 11, 2012Date of Patent: November 19, 2013Assignees: Genexine, Inc., Postech Academy-Industry Foundation of Phohang University of Science and Technology (Postech)Inventors: Sehwan Yang, Young Chul Sung
-
Patent number: RE46453Abstract: The present invention relates to a fusion protein comprising a fusion polypeptide of E6 and E7 of a human papilloma virus, a signal peptide for secreting the polypeptide out of the cell, and an immune enhancing peptide for a subject; a polynucleotide encoding the fusion protein; and a vector containing the polynucleotide. The present invention further relates to a pharmaceutical composition comprising the fusion protein or the vector; and a method for treating a disease caused by a human papilloma virus using the pharmaceutical composition.Type: GrantFiled: February 25, 2015Date of Patent: June 27, 2017Assignees: POSTECH FOUNDATION, GENEXINE, INC.Inventors: Young Chul Sung, Hyun Tak Jin, Sang Hwan Seo, Sang Hoon Park, Je-In Youn